Renal anemia is a common complication of chronic renal failure caused by erythropoietin deficiency; targeting erythropoietin is a common approach to renal anemia treatment. This paper describes the role of erythropoietin and others drugs in renal anemia treatment, as well as the cause of erythropoietin resistance.

Erythropoiesis stimulating agents are widely used for the treatment of anemia. Recently, we reported erythroid expansion with impaired B lymphopoiesis and loss of trabecular bone in C57BL/6 mice following ten days of treatment with low-dose short acting recombinant human erythropoietin. We have assessed erythropoietin against longer-acting darbepoietin-alfa at a comparable erythroid stimulatory...

BACKGROUND A costly component of end-stage renal disease care is anemia management with recombinant human erythropoietin. National Kidney Foundation clinical practice guidelines recommend that erythropoietin be administered subcutaneously, rather than intravenously, given that the target hemoglobin level can be maintained with a lower subcutaneous dose. Because reimbursement for erythropoietin ...

BACKGROUND Recent data suggests that erythropoietin therapy may actually retard the progression of chronic kidney disease (CKD). Transplant recipients with evidence of chronic allograft dysfunction could respond in a similar manner to erythropoietin. METHODS We evaluated 166 individuals who initiated erythropoietin therapy after at least 18 days of transplant function. One hundred and nine in...

The full-length murine erythropoietin receptor was expressed in Spodoptera frugiperda (Sf9) cells using a recombinant baculovirus vector. Erythropoietin receptor protein production was maximal 48 hours after infection, as determined by metabolic labeling and immunoblotting; receptor protein varied in molecular mass from 62 to 76 kD. Erythropoietin receptors produced in Sf9 cells could be solubi...

the effect of intravenous and oral iron administration on responsiveness to synthetic erythropoietin in treatment of hemodialysis patients' anemia     shariati ar [1] , asayesh h [2] , mojerloo m [3] , karimi taleghani h [4]     received: 10june, 2011 accepted: august 28, 2011     abstract   background & aims : inadequate production of erythropoietin is the main cause of anemia in chronic ...

background: ischemic brain strokes consisttwo‑thirdsof strokesand their complications bear a lot of disability for patient and society. in this study, we seek for effect of erythropoietin on ischemic brain stroke’s outcomes according to national institutes of health stroke scale (nihss) changes. methods: this study is a rct (randomized clinical trial). all patients with focal neurologic deficit...

BACKGROUND Chronic renal failure leads to hyporegenerative anemia due to erythropoietin deficiency. The creatinine clearance and hemoglobin levels, at which anemia treatment with recombinant erythropoietin should be started, are unclear. Interpretation of serum erythropoietin levels in the context of renal insufficiency remains controversial and was addressed in this study. METHODS Three hund...

The in vitro plasma clot technique was employed to examine the role of calcium during the interaction of erythropoietin and mouse erythroid progenitor cells. Erythropoietin-induced erythroid colony formation was increased 24% by the carboxylic ionophore A23187 (10 nM), whereas a 35% increase was produced by the carboxylic ionophore Ro 2-2985/1 (1 nM). EGTA (3 mM) inhibited erythropoietin-induce...

Delayed erythroid recovery is common after bone marrow transplantation (BMT), with some patients continuing to require red blood cell (RBC) transfusion support for as long as 1 year. While the etiology is multifactorial, inadequate stimulation of erythroid progenitors by the erythroid growth factor, erythropoietin, may play a role. In this study, the erythropoietin response to anemia of 70 cons...